![Insulet Corporation Website](https://cdn.finchat.io/618908.png)
Insulet Corporation
NasdaqGS-PODD
Company Overview
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Name
Insulet Corporation
CEO
Dr. James R. Hollingshead Ph.D.
Website
www.insulet.com
Sector
Health Care Equipment and Supplies
Year Founded
2000
Profile
Market Cap
$15.14B
EV
$15.75B
Shares Out
70.04M
Revenue
$1,872.7M
Employees
3,000
Margins
Gross
68.39%
EBITDA
19.44%
Operating
15.41%
Pre-Tax
14.28%
Net
21.11%
FCF
10.22%
Returns (5Yr Avg)
ROA
2.56%
ROTA
11.92%
ROE
10.4%
ROCE
6.77%
ROIC
9.54%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
$236.85
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
$821M
Net Debt
$612.1M
Debt/Equity
1.44
EBIT/Interest
7.44
Growth (CAGR)
Rev 3Yr
23.44%
Rev 5Yr
23.47%
Rev 10Yr
21.33%
Dil EPS 3Yr
126.44%
Dil EPS 5Yr
82.44%
Dil EPS 10Yr
17.6%
Rev Fwd 2Yr
18.37%
EBITDA Fwd 2Yr
25.66%
EPS Fwd 2Yr
17.56%
EPS LT Growth Est
28.2%
Dividends
Yield
—
Payout
—
DPS
—
DPS Growth 3Yr
—
DPS Growth 5Yr
—
DPS Growth 10Yr
—
DPS Growth Fwd 2Yr
—